Frontiers in Public Health (Aug 2022)
Expert consensus statement on therapeutic drug monitoring and individualization of linezolid
- Bin Lin,
- Bin Lin,
- Yangmin Hu,
- Ping Xu,
- Tao Xu,
- Chunyan Chen,
- Le He,
- Mi Zhou,
- Zhangzhang Chen,
- Chunhong Zhang,
- Xuben Yu,
- Luo Fang,
- Junfeng Zhu,
- Yanlan Ji,
- Qun Lin,
- Hengbin Cao,
- Youqin Dai,
- Xiaoyan Lu,
- Changcheng Shi,
- Li Li,
- Changjiang Wang,
- Xumei Li,
- Qiongyan Fang,
- Jing Miao,
- Zhengyi Zhu,
- Guangyong Lin,
- Haichao Zhan,
- Shiwen Lv,
- Yalan Zhu,
- Xinjun Cai,
- Yin Ying,
- Meng Chen,
- Qiong Xu,
- Yiwen Zhang,
- Yubin Xu,
- Pea Federico,
- Pea Federico,
- Saiping Jiang,
- Haibin Dai,
- Haibin Dai
Affiliations
- Bin Lin
- Department of Pharmacy, Changxing People's Hospital, Changxing Branch, Second Affiliated Hospital of Zhejiang University School of Medicine, Huzhou, China
- Bin Lin
- Key Laboratory of Intelligent Pharmacy and Individualized Therapy of Huzhou, Huzhou, China
- Yangmin Hu
- Department of Pharmacy, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
- Ping Xu
- Department of Pharmacy, Ningbo First Hospital, Ningbo, China
- Tao Xu
- Department of Pharmacy, Ningbo First Hospital, Ningbo, China
- Chunyan Chen
- Department of Pharmacy, Ningbo First Hospital, Ningbo, China
- Le He
- Department of Pharmacy, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Mi Zhou
- Department of Pharmacy, Children's Hospital of Soochow University, Suzhou, China
- Zhangzhang Chen
- Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China
- Chunhong Zhang
- Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- Xuben Yu
- Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- Luo Fang
- Department of Pharmacy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China
- Junfeng Zhu
- Department of Pharmacy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China
- Yanlan Ji
- 0Department of Pharmacy, Deqing People's Hospital, Huzhou, China
- Qun Lin
- 1Department of Pharmacy, Tiantai People's Hospital, Taizhou, China
- Hengbin Cao
- 2Department of Clinical Pharmacy, Huzhou Central Hospital, Huzhou, China
- Youqin Dai
- 3Department of Pharmacy, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, China
- Xiaoyan Lu
- 3Department of Pharmacy, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, China
- Changcheng Shi
- 4Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Li Li
- 5Department of Pharmacy, Zhejiang Hospital, Hangzhou, China
- Changjiang Wang
- 6Department of Pharmacy, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China
- Xumei Li
- 6Department of Pharmacy, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China
- Qiongyan Fang
- 7Department of Pharmacy, Zhoushan Hospital, Zhoushan, China
- Jing Miao
- 8Department of Pharmacy, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
- Zhengyi Zhu
- 8Department of Pharmacy, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China
- Guangyong Lin
- 9Department of Pharmacy, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- Haichao Zhan
- 0Department of Clinical Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
- Shiwen Lv
- 0Department of Clinical Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
- Yalan Zhu
- 0Department of Clinical Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
- Xinjun Cai
- 1Department of Pharmacy, Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Yin Ying
- 2Department of Pharmacy, Tongde Hospital of Zhejiang Province, Hangzhou, China
- Meng Chen
- 3Department of Pharmacy, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing, China
- Qiong Xu
- 4Department of Pharmacy, Putuo Hospital, Zhoushan, China
- Yiwen Zhang
- 5Clinical Pharmacy Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China
- Yubin Xu
- 6Department of Pharmacy, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China
- Pea Federico
- 7Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy
- Pea Federico
- 8SSD Clinical Pharmacology, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- Saiping Jiang
- 9Department of Clinical Pharmacy, First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
- Haibin Dai
- Key Laboratory of Intelligent Pharmacy and Individualized Therapy of Huzhou, Huzhou, China
- Haibin Dai
- Department of Pharmacy, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
- DOI
- https://doi.org/10.3389/fpubh.2022.967311
- Journal volume & issue
-
Vol. 10
Abstract
Linezolid is an oxazolidinone antibacterial drug, and its therapeutic drug monitoring and individualized treatment have been challenged since its approval. With the in-depth clinical research of linezolid, we have changed our attitude toward its therapeutic drug monitoring and our view of individualized treatment. On the basis of summarizing the existing clinical studies, and based on the practical experience of each expert in their respective professional fields, we have formed this expert consensus. Our team of specialists is a multidisciplinary team that includes pharmacotherapists, clinical pharmacology specialists, critical care medicine specialists, respiratory specialists, infectious disease specialists, emergency medicine specialists and more. We are committed to the safe and effective use of linezolid in patients in need, and the promotion of its therapeutic drug monitoring.
Keywords
